article

1. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial..  JAMA neurology.  78:312-320. 2021
2. Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease..  Neurobiology of disease.  -. 2021
3. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned..  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.  17:1393-1405. 2020
4. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study..  Journal of Parkinson's disease.  10:505-510. 2020
5. Barriers and Motivators to Engage in Exercise for Persons with Parkinson's Disease..  Journal of Parkinson's disease.  10:1293-1299. 2020
6. Big health data and Parkinson's disease epidemiology: Challenges and opportunities..  Parkinsonism & related disorders.  58-59. 2020
7. Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression?.  Frontiers in aging neuroscience.  -. 2020
8. Correction: Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists..  Genetics in medicine : official journal of the American College of Medical Genetics.  22:-. 2020
9. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD)..  Annals of clinical and translational neurology.  8:308-320. 2020
10. Diet pattern and prodromal features of Parkinson disease..  Neurology.  95:e2095-e2108. 2020
11. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?.  Neurology.  94:481-494. 2020
12. Does Serum Urate Change as Parkinson's Disease Progresses?.  Journal of Parkinson's disease.  10:1571-1576. 2020
13. GBA.  Neurology.  95:e685-e696. 2020
14. If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?.  Movement disorders : official journal of the Movement Disorder Society.  35:1727-1730. 2020
15. Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients..  Frontiers in neurology.  -. 2020
16. LRRK2.  Neurology.  95:e3428-e3437. 2020
17. Long-Term Use of Antibiotics and Risk of Parkinson's Disease in the Nurses' Health Study..  Parkinson's disease.  -. 2020
18. Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease..  Journal of Parkinson's disease.  10:1011-1021. 2020
19. Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis..  Amyotrophic lateral sclerosis & frontotemporal degeneration.  22:133-143. 2020
20. Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists..  Genetics in medicine : official journal of the American College of Medical Genetics.  22:574-580. 2019
21. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease..  Annals of neurology.  85:593-599. 2019
22. Lifestyle and Parkinson's disease progression..  Movement disorders : official journal of the Movement Disorder Society.  34:7-8. 2019
23. Physical activity and prodromal features of Parkinson disease..  Neurology.  93:e2157-e2169. 2019
24. Plasma urate concentrations and possible REM sleep behavior disorder..  Annals of clinical and translational neurology.  6:2368-2376. 2019
25. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis..  Neurology.  92:e2089-e2100. 2019
26. Reply to "Mitochondrial DNA deletions discriminate affected from unaffected LRRK2 mutation carriers"..  Annals of neurology.  86:326-327. 2019
27. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases..  Neurology.  92:329-337. 2019
28. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial..  Neurology.  93:e1328-e1338. 2019
29. Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women..  Movement disorders : official journal of the Movement Disorder Society.  33:1492-1496. 2018
30. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice..  EBioMedicine.  13-22. 2018
31. Cardiovascular Safety of Febuxostat..  The New England journal of medicine.  379:-. 2018
32. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease..  EBioMedicine.  259-268. 2018
33. Genetic variants related to urate and risk of Parkinson's disease..  Parkinsonism & related disorders.  4-9. 2018
34. Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts..  Neurology.  90:e1646-e1653. 2018
35. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk..  Movement disorders : official journal of the Movement Disorder Society.  33:414-420. 2018
36. Non-motor features of Parkinson's disease in a nested case-control study of US men..  Journal of neurology, neurosurgery, and psychiatry.  89:1288-1295. 2018
37. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis..  Annals of clinical and translational neurology.  5:1522-1533. 2018
38. Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis..  Neurology.  92:e2081-e2088. 2018
39. The association between restless legs syndrome and premotor symptoms of Parkinson's disease..  Journal of the neurological sciences.  41-44. 2018
40. Air Pollution and Risk of Parkinson's Disease in a Large Prospective Study of Men..  Environmental health perspectives.  125:-. 2017
41. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials..  Movement disorders : official journal of the Movement Disorder Society.  32:319-324. 2017
42. Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?.  Journal of Parkinson's disease.  7:79-80. 2017
43. Dietary antioxidants and Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  32:1501-1503. 2017
44. Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use..  Journal of Parkinson's disease.  7:677-684. 2017
45. Intake of dairy foods and risk of Parkinson disease..  Neurology.  89:46-52. 2017
46. KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients..  Proceedings of the National Academy of Sciences of the United States of America.  114:E4676-E4685. 2017
47. MC1R.  Annals of clinical and translational neurology.  4:212-216. 2017
48. Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis..  Amyotrophic lateral sclerosis & frontotemporal degeneration.  19:194-200. 2017
49. Targeting urate to reduce oxidative stress in Parkinson disease..  Experimental neurology.  298:210-224. 2017
50. The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival..  Annals of neurology.  81:395-406. 2017
51. Urate as a Marker of Risk and Progression of Neurodegenerative Disease..  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.  14:148-153. 2017
52. Intake of antioxidant vitamins and risk of Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  31:1909-1914. 2016
53. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors..  Neuroscience.  129-37. 2016
54. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  31:417-21. 2016
55. Prospective study of plasma urate and risk of Parkinson disease in men and women..  Neurology.  86:520-6. 2016
56. Purines: forgotten mediators in traumatic brain injury..  Journal of neurochemistry.  137:142-53. 2016
57. Serum urate at trial entry and ALS progression in EMPOWER..  Amyotrophic lateral sclerosis & frontotemporal degeneration.  18:120-125. 2016
58. The epidemiology of Parkinson's disease: risk factors and prevention..  The Lancet. Neurology.  15:1257-1272. 2016
59. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease..  Brain : a journal of neurology.  138:2659-71. 2015
60. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release..  Neurobiology of disease.  574-579. 2015
61. The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia..  PloS one.  10:-. 2015
62. A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses' health study cohort..  Environmental health perspectives.  122:933-8. 2014
63. Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease..  Brain research.  103-9. 2014
64. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss..  PloS one.  9:-. 2014
65. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial..  JAMA neurology.  71:141-50. 2014
66. Mendelian randomization of serum urate and parkinson disease progression..  Annals of neurology.  76:862-8. 2014
67. Particulate matter and risk of Parkinson disease in a large prospective study of women..  Environmental health : a global access science source.  -. 2014
68. Protection by inosine in a cellular model of Parkinson's disease..  Neuroscience.  242-9. 2014
69. Restless legs syndrome: an early clinical feature of Parkinson disease in men..  Sleep.  37:369-72. 2014
70. Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?.  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.  11:34-46. 2014
71. Urate and neuroprotection trials..  The Lancet. Neurology.  13:-. 2014
72. Caffeine consumption and risk of dyskinesia in CALM-PD..  Movement disorders : official journal of the Movement Disorder Society.  28:380-3. 2013
73. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments..  Journal of Parkinson's disease.  3:231-9. 2013
74. Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders..  Neuro-degenerative diseases.  12:189-98. 2013
75. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study..  Neurology.  81:1531-7. 2013
76. Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease..  Annals of neurology.  71:278-82. 2012
77. Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes..  Glia.  60:702-16. 2012
78. Age, statin use, and the risk for incident Parkinson disease-reply..  Archives of neurology.  69:-. 2012
79. Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women..  Movement disorders : official journal of the Movement Disorder Society.  27:980-7. 2012
80. Caffeine and risk of Parkinson's disease in a large cohort of men and women..  Movement disorders : official journal of the Movement Disorder Society.  27:1276-82. 2012
81. Caffeine in Parkinson disease: better for cruise control than snooze patrol?.  Neurology.  79:616-8. 2012
82. Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor..  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.  23:972-7. 2012
83. Declining quality of life in Parkinson disease before and after diagnosis..  Journal of Parkinson's disease.  2:153-60. 2012
84. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration..  Proceedings of the National Academy of Sciences of the United States of America.  110:300-5. 2012
85. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  27:1392-7. 2012
86. Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection..  Biomedical chromatography : BMC.  27:122-9. 2012
87. Habitual intake of dietary flavonoids and risk of Parkinson disease..  Neurology.  78:1138-45. 2012
88. Prospective study of statin use and risk of Parkinson disease..  Archives of neurology.  69:380-4. 2012
89. Protection of dopaminergic cells by urate requires its accumulation in astrocytes..  Journal of neurochemistry.  123:172-81. 2012
90. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease..  PloS one.  7:-. 2012
91. Urate in Parkinson's disease: more than a biomarker?.  Current neurology and neuroscience reports.  12:367-75. 2012
92. A prospective study of bowel movement frequency and risk of Parkinson's disease..  American journal of epidemiology.  174:546-51. 2011
93. Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study..  Movement disorders : official journal of the Movement Disorder Society.  26:2283-6. 2011
94. Obesity, diabetes, and risk of Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  26:2253-9. 2011
95. Preclinical jockeying on the translational track of adenosine A2A receptors..  Experimental neurology.  228:160-4. 2011
96. Serum cholesterol and the progression of Parkinson's disease: results from DATATOP..  PloS one.  6:-. 2011
97. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease"..  Movement disorders : official journal of the Movement Disorder Society.  26:1864-8. 2011
98. Use of ibuprofen and risk of Parkinson disease..  Neurology.  76:863-9. 2011
99. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration..  Experimental neurology.  223:657-61. 2010
100. Calcium channel blocker use and risk of Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  25:1818-22. 2010
101. Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease..  Brain research.  310-8. 2010
102. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease..  Neuroscience.  167:475-81. 2010
103. Pathophysiological roles for purines: adenosine, caffeine and urate..  Progress in brain research.  183-208. 2010
104. Plasma urate and Parkinson's disease in women..  American journal of epidemiology.  172:666-70. 2010
105. Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women..  Parkinsonism & related disorders.  16:370-5. 2010
106. Prenatal and early life factors and risk of Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  25:1560-7. 2010
107. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease..  Neuroscience letters.  486:161-5. 2010
108. Rasagiline in Parkinson's disease..  The New England journal of medicine.  362:658; author reply 658-9. 2010
109. Restless legs syndrome and Parkinson's disease in men..  Movement disorders : official journal of the Movement Disorder Society.  25:2654-7. 2010
110. Restless legs syndrome and erectile dysfunction..  Sleep.  33:75-9. 2010
111. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?.  Neurology.  75:1943-4; author reply 1944-5. 2010
112. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis..  Biomarkers in medicine.  4:701-12. 2010
113. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease..  Journal of neuropathology and experimental neurology.  68:515-24. 2009
114. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease..  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.  6:141-51. 2009
115. Family history of melanoma and Parkinson disease risk..  Neurology.  73:1286-91. 2009
116. Genetic determinants of hair color and Parkinson's disease risk..  Annals of neurology.  65:76-82. 2009
117. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease..  Journal of neurochemistry.  111:1478-89. 2009
118. Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway..  TheScientificWorldJournal.  1321-44. 2009
119. Obesity and restless legs syndrome in men and women..  Neurology.  72:1255-61. 2009
120. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  24:1359-65. 2009
121. Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality..  American journal of epidemiology.  169:678-82. 2009
122. Urate as a predictor of the rate of clinical decline in Parkinson disease..  Archives of neurology.  66:1460-8. 2009
123. Adenosine A1 and A2A receptor regulation of protein phosphatase 2A in the murine heart..  Journal of cellular physiology.  216:83-90. 2008
124. Diet, urate, and Parkinson's disease risk in men..  American journal of epidemiology.  167:831-8. 2008
125. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007..  Environmental health perspectives.  117:117-21. 2008
126. Mice heterozygous for both A1 and A(2A) adenosine receptor genes show similarities to mice given long-term caffeine..  Journal of applied physiology (Bethesda, Md. : 1985).  106:631-9. 2008
127. Perceived imbalance and risk of Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  23:613-6. 2008
128. Plasma urate and progression of mild cognitive impairment..  Neuro-degenerative diseases.  6:23-8. 2008
129. Recreational physical activity and risk of Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  23:69-74. 2008
130. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease..  Archives of neurology.  65:716-23. 2008
131. Telomere length and risk of Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  23:302-5. 2008
132. Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus..  Journal of neurochemistry.  104:279-86. 2007
133. Adenosine A2A antagonists as neurotherapeutics: crossing the bridge..  Progress in neurobiology.  83:261-2. 2007
134. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?.  Current opinion in neurology.  20:477-83. 2007
135. Consumption of dairy products and risk of Parkinson's disease..  American journal of epidemiology.  165:998-1006. 2007
136. Erectile function and risk of Parkinson's disease..  American journal of epidemiology.  166:1446-50. 2007
137. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease..  Neurology.  69:1688-95. 2007
138. Molecular markers of early Parkinson's disease based on gene expression in blood..  Proceedings of the National Academy of Sciences of the United States of America.  104:955-60. 2007
139. Peripheral inflammatory biomarkers and risk of Parkinson's disease..  American journal of epidemiology.  167:90-5. 2007
140. Plasma urate and risk of Parkinson's disease..  American journal of epidemiology.  166:561-7. 2007
141. Prospective study of dietary pattern and risk of Parkinson disease..  The American journal of clinical nutrition.  86:1486-94. 2007
142. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications..  Progress in neurobiology.  83:293-309. 2007
143. Temporal relationship between cigarette smoking and risk of Parkinson disease..  Neurology.  68:764-8. 2007
144. A prospective study of night shift work, sleep duration, and risk of Parkinson's disease..  American journal of epidemiology.  163:726-30. 2006
145. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis..  British journal of pharmacology.  148:1144-55. 2006
146. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma..  Arthritis and rheumatism.  54:2632-42. 2006
147. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease..  The Journal of neuroscience : the official journal of the Society for Neuroscience.  26:535-41. 2006
148. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice..  The Journal of neuroscience : the official journal of the Society for Neuroscience.  26:13548-55. 2006
149. Novel pharmacological targets for the treatment of Parkinson's disease..  Nature reviews. Drug discovery.  5:845-54. 2006
150. Pesticide exposure and risk for Parkinson's disease..  Annals of neurology.  60:197-203. 2006
151. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals..  Movement disorders : official journal of the Movement Disorder Society.  21:1002-7. 2006
152. Targeting adenosine A2A receptors in Parkinson's disease..  Trends in neurosciences.  29:647-54. 2006
153. (E)-8-(3-Chlorostyryl)-1,3,7-trimethylxanthine, a caffeine derivative acting both as antagonist of adenosine A2A receptors and as inhibitor of MAO-B..  Acta crystallographica. Section C, Crystal structure communications.  61:o531-2. 2005
154. A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization..  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.  30:891-900. 2005
155. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience..  Drugs & aging.  22:471-82. 2005
156. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia..  Journal of neurochemistry.  95:919-29. 2005
157. Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects..  Journal of neurochemistry.  95:1188-200. 2005
158. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine..  Nature neuroscience.  8:858-9. 2005
159. Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice..  Neuroscience letters.  393:31-5. 2005
160. Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum..  Physiological genomics.  23:89-102. 2005
161. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice..  The Journal of neuroscience : the official journal of the Society for Neuroscience.  25:10414-9. 2005
162. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease..  Annals of neurology.  58:963-7. 2005
163. Physical activity and the risk of Parkinson disease..  Neurology.  64:664-9. 2005
164. Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses..  Brain research.  1000:156-73. 2004
165. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32..  Molecular pharmacology.  65:121-9. 2004
166. Folate intake and risk of Parkinson's disease..  American journal of epidemiology.  160:368-75. 2004
167. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage..  Journal of neurochemistry.  88:538-44. 2004
168. Obesity and the risk of Parkinson's disease..  American journal of epidemiology.  159:547-55. 2004
169. Tetanus toxin fragment C as a vector to enhance delivery of proteins to the CNS..  Brain research.  1011:7-13. 2004
170. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease..  Pharmacology & therapeutics.  105:267-310. 2004
171. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease..  Experimental neurology.  184:285-94. 2003
172. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease..  Neurology.  61:S74-81. 2003
173. Alcohol consumption and the incidence of Parkinson's disease..  Annals of neurology.  54:170-5. 2003
174. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease..  Neurology.  60:790-5. 2003
175. DARPP chocolate: a caffeinated morsel of striatal signaling..  Science's STKE : signal transduction knowledge environment.  2003:-. 2003
176. Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization..  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.  28:1086-95. 2003
177. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists..  Bioorganic & medicinal chemistry.  11:1299-310. 2003
178. Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists..  Neurology.  61:S62-8. 2003
179. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice..  Neurobiology of aging.  24:245-58. 2003
180. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease..  Neurology.  61:S55-61. 2003
181. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease..  Archives of neurology.  60:1059-64. 2003
182. Prospective study of phobic anxiety and risk of Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  18:646-51. 2003
183. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells..  The Journal of clinical investigation.  112:883-91. 2003
184. Sleep regulation in adenosine A2A receptor-deficient mice..  Neurology.  61:S94-6. 2003
185. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism..  The Journal of biological chemistry.  277:36040-4. 2002
186. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors..  The American journal of pathology.  160:2009-18. 2002
187. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD..  Neurology.  58:1154-60. 2002
188. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice..  Neuroscience letters.  322:13-6. 2002
189. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors..  The Journal of neuroscience : the official journal of the Society for Neuroscience.  22:1054-62. 2002
190. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin..  The American journal of pathology.  160:2231-44. 2002
191. Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice..  The Biochemical journal.  354:123-30. 2001
192. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease..  The Journal of neuroscience : the official journal of the Society for Neuroscience.  21:-. 2001
193. The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures..  Parkinsonism & related disorders.  8:19-22. 2001
194. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice..  Proceedings of the National Academy of Sciences of the United States of America.  98:1970-5. 2001
195. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms..  FASEB journal : official publication of the Federation of American Societies for Experimental Biology.  14:2065-74. 2000
196. Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons..  Journal of neurochemistry.  74:2528-36. 2000
197. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors..  Neuroscience.  97:195-204. 2000
198. Study of A(2A) adenosine receptor gene deficient mice reveals that adenosine analogue CGS 21680 possesses no A(2A) receptor-unrelated lymphotoxicity..  British journal of pharmacology.  131:43-50. 2000
199. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice..  The Journal of neuroscience : the official journal of the Society for Neuroscience.  19:9192-200. 1999
200. Contrasting calcium dependencies of SAPK and ERK activations by glutamate in cultured striatal neurons..  Journal of neurochemistry.  72:2248-55. 1999
201. Glutamate, but not dopamine, stimulates stress-activated protein kinase and AP-1-mediated transcription in striatal neurons..  The Journal of neuroscience : the official journal of the Society for Neuroscience.  17:3455-66. 1997
202. Normal-pressure hydrocephalus with misleading features of irreversible dementias: a case report..  Journal of geriatric psychiatry and neurology.  10:51-4. 1997
203. Hemiballismus..  AJNR. American journal of neuroradiology.  15:1377-82. 1994
204. Leukemia inhibitory factor and ciliary neurotrophic factor increase activated Ras in a neuroblastoma cell line and in sympathetic neuron cultures..  Journal of neurochemistry.  63:1246-54. 1994
205. Effects of peptides of the secretin-glucagon family and cyclic nucleotides on tyrosine hydroxylase activity in sympathetic nerve endings..  Journal of neurochemistry.  56:400-6. 1991
206. Activation of ganglionic tyrosine hydroxylase by peptides of the secretin-glucagon family: structure-function studies..  Neuroscience.  31:159-67. 1989
207. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation..  Annual review of neuroscience.  415-61. 1989
208. Secretin and vasoactive intestinal peptide activate tyrosine hydroxylase in sympathetic nerve endings..  The Journal of neuroscience : the official journal of the Society for Neuroscience.  9:160-6. 1989
209. Both synaptic and antidromic stimulation of neurons in the rat superior cervical ganglion acutely increase tyrosine hydroxylase activity..  Neuroscience.  25:207-15. 1988